Focetria

Phase 3Biologic

CChiltern Pesquisa Clinica Ltda

Focetria is one of 178 biologic programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

177

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

HIV-1 InfectionActive, not recruiting

Diabetes MellitusActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

InfluenzaActive, not recruiting

Rheumatic DiseasePhase 2

Active, not recruiting

HIV-1 InfectionPhase 3

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Focetria

CChiltern Pesquisa Clinica Ltda

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Completed·CChiltern Pesquisa Clinica Ltda·Phase 3·NCT01032395·342 enrolled

Inflammatory Bowel Disease1 trial

Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT01019837·200 enrolled

Transplant Recipient1 trial

H1N1sw Vaccine in Adult Transplant Recipients

Terminated·HHepNet Study House, German Liverfoundation·Phase 2·NCT01069601·13 enrolled

Rheumatic Disease1 trial

Vaccination Against Influenza H1N1 in Rheumatic Diseases

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01006681·400 enrolled

Influenza1 trial

H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women

Completed·CCopenhagen Studies on Asthma in Childhood·N/A·NCT01012557·296 enrolled

1 more indication

HIV-1 infection1 trial

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

Completed·CChiltern Pesquisa Clinica Ltda·Phase 3·NCT01032408·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Focetria. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Focetria compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Focetria. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chiltern Pesquisa Clinica Ltda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CChiltern Pesquisa Clinica Ltda

Focetria

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetes Mellitus1 trial

Inflammatory Bowel Disease1 trial

Transplant Recipient1 trial

Rheumatic Disease1 trial

Influenza1 trial

HIV-1 infection1 trial

References

Drug Info

Quick Facts

Related News